APOC3, coronary disease, and complexities of Mendelian randomization.

  title={APOC3, coronary disease, and complexities of Mendelian randomization.},
  author={Jonathan C. Cohen and Stefan Stender and Helen H. Hobbs},
  journal={Cell metabolism},
  volume={20 3},
Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy. 
22 Citations
5 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 22 extracted citations


Publications referenced by this paper.
Showing 1-5 of 5 references

2014) now demonstrate that glutamine- and glucose-dependent nucleotide synthesis segre

  • Oburoglu
  • 2014


  • Heart, Lung, Blood Institute
  • Engl. J. Med. 371, 22–31. Di Angelantonio, E…
  • 2014

UK10K consortium

  • I. Tachmazidou, G. Dedoussis, +7 authors Y Chen
  • 2013
2 Excerpts

Jama 302, 1993–2000

  • Risk Factors Collaboration
  • Frikke-Schmidt, R., Nordestgaard, B.G., Stene, M…
  • 2009

Lancet 380 , 572 – 580 . Stem Cell Lineage Specification : You Become What You Eat Clifford D

  • G. M. Peloso, M. Orho-Melander, +6 authors T. Johnson
  • Nat Commun

Similar Papers

Loading similar papers…